Quinn Opportunity Partners LLC Revance Therapeutics, Inc. Transaction History
Quinn Opportunity Partners LLC
- $939 Million
- Q3 2024
A detailed history of Quinn Opportunity Partners LLC transactions in Revance Therapeutics, Inc. stock. As of the latest transaction made, Quinn Opportunity Partners LLC holds 110,113 shares of RVNC stock, worth $282,990. This represents 0.03% of its overall portfolio holdings.
Number of Shares
110,113
Previous 10,000
1001.13%
Holding current value
$282,990
Previous $25,000
1028.0%
% of portfolio
0.03%
Previous 0.0%
Shares
11 transactions
Others Institutions Holding RVNC
# of Institutions
232Shares Held
82.1MCall Options Held
680KPut Options Held
896K-
Black Rock Inc. New York, NY8.57MShares$22 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.73MShares$14.7 Million0.0% of portfolio
-
Franklin Resources Inc San Mateo, CA4.78MShares$12.3 Million0.0% of portfolio
-
Fil LTD Hamilton, D04.19MShares$10.8 Million0.01% of portfolio
-
Alpine Associates Management Inc. Englewood Cliffs, NJ4.16MShares$10.7 Million0.49% of portfolio
About Revance Therapeutics, Inc.
- Ticker RVNC
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 82,305,696
- Market Cap $212M
- Description
- Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DaxibotulinumtoxinA for injection, which has completed phase III clinical trials fo...